Request Demo

Last update 08 May 2025

Periostitis

Last update 08 May 2025

Basic Info

Synonyms

PERIOSTEITIS, PERIOSTITIS, Periostalgia

+ [12]

Introduction

Inflammation of the periosteum. The condition is generally chronic, and is marked by tenderness and swelling of the bone and an aching pain. Acute periostitis is due to infection, is characterized by diffuse suppuration, severe pain, and constitutional symptoms, and usually results in necrosis. (Dorland, 27th ed)

Drugs associated with Periostitis

CN118619954

Patent Mining

Target

DDR1

Mechanism-

Active Org.

Beijing Youzhuju Network Technology Co Ltd.

Originator Org.

Beijing Youzhuju Network Technology Co Ltd.

Active Indication

Digestive System Disorders [+5]

Inactive Indication-

Drug Highest PhaseDiscovery

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Periostitis

CTR20201546

/ CompletedNot Applicable

头孢克洛缓释片（375mg）随机、开放、两制剂、两周期、双交叉在健康人体空腹和餐后条件下生物等效性试验

[Translation] A randomized, open-label, two-dose, two-period, double-crossover bioequivalence study of cefaclor extended-release tablets (375 mg) in healthy volunteers under fasting and fed conditions

1）评价在空腹和餐后给药条件下，受试制剂头孢克洛缓释片（商品名：新达罗®，山东淄博新达制药有限公司生产）375mg和参比制剂头孢克洛缓释片（II）（商品名：希刻劳®，苏州西克罗制药有限公司生产）375mg在中国健康受试者中的生物等效性； 2）观察空腹和餐后条件下口服受试制剂头孢克洛缓释片375mg和参比制剂头孢克洛缓释片（II）375mg在健康受试者中的安全性。

[Translation]

1) To evaluate the bioequivalence of the test preparation Cefaclor Sustained-Release Tablets (trade name: Xindalu®, produced by Shandong Zibo Xinda Pharmaceutical Co., Ltd.) 375 mg and the reference preparation Cefaclor Sustained-Release Tablets (II) (trade name: Xikeluo®, produced by Suzhou Xikeluo Pharmaceutical Co., Ltd.) 375 mg in healthy Chinese subjects under fasting and postprandial administration conditions; 2) To observe the safety of the test preparation Cefaclor Sustained-Release Tablets 375 mg and the reference preparation Cefaclor Sustained-Release Tablets (II) 375 mg in healthy subjects under fasting and postprandial conditions.

Start Date04 Aug 2020

Sponsor / Collaborator

Shandong Zibo Xincat Pharmaceutical Co., Ltd.

CTR20181962

/ CompletedNot Applicable

健康受试者空腹和餐后单次口服头孢克洛缓释片人体生物等效性研究

[Translation] A bioequivalence study of single oral administration of cefaclor sustained-release tablets in healthy volunteers after fasting and feeding

主要目的：评估中国健康受试者空腹和餐后状态下口服浙江昂利康制药股份有限公司生产的头孢克洛缓释片（受试制剂）和礼来苏州制药有限公司生产的头孢克洛缓释片（II）（参比制剂，商品名：希刻劳® )的生物等效性。次要目的：观察空腹和餐后口服受试制剂和参比制剂的安全性。

[Translation]

Primary objective: To evaluate the bioequivalence of cefaclor extended-release tablets (test preparation) produced by Zhejiang Anlikang Pharmaceutical Co., Ltd. and cefaclor extended-release tablets (II) (reference preparation, trade name: Cefaclor®) produced by Eli Lilly Suzhou Pharmaceutical Co., Ltd. in Chinese healthy subjects in fasting and fed state. Secondary objective: To observe the safety of the test preparation and reference preparation in fasting and fed state.

Start Date03 Nov 2018

Sponsor / Collaborator

Zhejiang Anglikang Pharmaceutical Co. Ltd.

NL-OMON36565

/ CompletedNot Applicable

The effectiveness of Pulsed Electromagnetic Field in the treatment of medial tibial stress syndrome: a pilot study. - The effectiveness of PEMF in the treatment of MTSS.

Start Date01 Oct 2011

Sponsor / Collaborator

Universitair Medisch Centrum Groningen

100 Clinical Results associated with Periostitis

100 Translational Medicine associated with Periostitis

0 Patents (Medical) associated with Periostitis

988

Literatures (Medical) associated with Periostitis

01 Apr 2025·Nature Reviews Rheumatology

Delineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis

Review

Author: Aydin, Sibel Zehra ; Di Matteo, Andrea ; David, Paula ; McGonagle, Dennis ; Zabotti, Alen

Psoriatic arthritis (PsA) is anatomically much more heterogeneous than rheumatoid arthritis, as, beyond synovitis, it often also involves enthesitis, peritendinitis, tenosynovitis, osteitis and periostitis. This heterogeneity currently precludes a gold standard for objectively defining resolution of inflammation following treatment, with enthesitis posing a particular challenge. Despite these difficulties, we apply lessons learned from rheumatoid arthritis to describe how patients with PsA and an inadequate response to therapy can be designated within two patient subgroups, characterized by persistent inflammatory PsA (PIPsA) and non-inflammatory PsA (NIPsA), respectively. The NIPsA phenotype is defined by the lack of ongoing joint inflammation, as confirmed through clinical assessment and imaging, along with normalized inflammatory marker levels. NIPsA might be associated with obesity, biomechanical-related pain, osteoarthritis, fibromyalgia, secondary post-inflammatory damage and central pain mechanisms. In this article, we frame PsA composite outcomes measures in relationship to the PIPsA and NIPsA phenotypes and propose that this approach might help to minimize unnecessary or ineffective cycling of PsA therapy in patients who acquire dominant non-inflammatory mechanisms and might also inform future trial design.

01 Mar 2025·ANZ Journal of Surgery

Increase in paediatric bone stress injuries: a single‐center study during the COVID‐19 pandemic

Article

Author: Donnan, Leo ; Morrison, Stewart ; Browne, Robert ; Behman, Amy

AbstractBackgroundMelbourne, Australia was considered the most locked‐down city during the COVID19 Pandemic. School was conducted from home and all organized sport ceased. Our institution noted an increased presentation of bone stress injuries (BSI) ranging from periostitis to stress fractures. This study reviews the prevalence of these injuries to gain insights into BSI presentation, diagnosis and best management.MethodsA retrospective review of lower limb long bone stress injuries between April 1st 2020 and March 31st 2022, and from 2018 to 2020 for comparison, was conducted. A chart review of those meeting inclusion criteria for demographics, fracture characteristics, investigations, and treatment administered was conducted.ResultsThirteen patients (two female, 11 male) met inclusion criteria. Only four patients were identified in the comparison period. The average age was 11.6 years, and average symptom duration was 7 weeks. Distinct morphologies were noted, specifically three discrete patterns of tibial injury were identified. Patients underwent an average of three imaging studies prior to diagnosis. Nine of 13 patients were prescribed a period of non‐weight bearing, averaging 3.5 weeks. Seven of 13 patients were prescribed a formal ‘partial weight bearing’ (50%) period averaging 6.4 weeks.ConclusionThere was a significant increase in paediatric BSI presentation over the COVID‐19 lockdowns. This may be linked to the effect of reduced physical activity. Knowledge of the three clear tibial morphologies identified in this study will inform future diagnosis and reduce investigation expenditure. These findings may inform public health measures during mandated lockdowns and raise a diagnostic framework for such injuries.

01 Mar 2025·Radiology Case Reports

Voriconazole-induced periostitis in the hand

Article

Author: Motamedi, Daria ; Singh, Gurbinder ; Sweetwood, Kevin

Voriconazole, a triazole antifungal, has proven effective against invasive fungal infections, and is often selected due to its enhanced antifungal spectrum coverage. Despite its general tolerability, voriconazole usage is associated with drug-induced periostitis, which presents with diffuse bone pain. This case report details a 65-year-old male on chronic immunosuppressive and antimicrobial therapy following heart transplant who developed hand pain. Identification of periostitis on hand radiographs and an acute elevation of alkaline phosphatase on subsequent blood analysis prompted discontinuation of voriconazole, resulting in a symptomatic and laboratory improvement. This case underscores the importance of leveraging a thorough understanding of imaging features, clinical manifestations, and laboratory data to aid in the diagnosis of voriconazole-induced periostitis.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Periostitis

Basic Info

Related

Analysis